DE69939748D1 - Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung - Google Patents

Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung

Info

Publication number
DE69939748D1
DE69939748D1 DE69939748T DE69939748T DE69939748D1 DE 69939748 D1 DE69939748 D1 DE 69939748D1 DE 69939748 T DE69939748 T DE 69939748T DE 69939748 T DE69939748 T DE 69939748T DE 69939748 D1 DE69939748 D1 DE 69939748D1
Authority
DE
Germany
Prior art keywords
multipartic
methylphenidate
composition
modified release
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939748T
Other languages
English (en)
Inventor
John G Devane
Niall M Fanning
Paul Stark
Singh Rekhi Gurvinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22312931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69939748(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Application granted granted Critical
Publication of DE69939748D1 publication Critical patent/DE69939748D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69939748T 1998-11-02 1999-11-01 Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung Expired - Lifetime DE69939748D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10672698P 1998-11-02 1998-11-02
PCT/US1999/025632 WO2000025752A1 (en) 1998-11-02 1999-11-01 Multiparticulate modified release composition

Publications (1)

Publication Number Publication Date
DE69939748D1 true DE69939748D1 (de) 2008-11-27

Family

ID=22312931

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939748T Expired - Lifetime DE69939748D1 (de) 1998-11-02 1999-11-01 Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung

Country Status (31)

Country Link
US (7) US6228398B1 (de)
EP (3) EP2020229A1 (de)
JP (2) JP4613275B2 (de)
KR (3) KR20080032661A (de)
CN (2) CN100444830C (de)
AR (1) AR021858A1 (de)
AT (1) ATE411011T3 (de)
AU (4) AU770645B2 (de)
BR (1) BRPI9914977B8 (de)
CA (2) CA2653839A1 (de)
CO (1) CO5261536A1 (de)
CY (1) CY1110421T1 (de)
CZ (1) CZ303495B6 (de)
DE (1) DE69939748D1 (de)
DK (1) DK1126826T6 (de)
ES (1) ES2313797T7 (de)
HK (1) HK1050487A1 (de)
HU (1) HU230454B1 (de)
ID (1) ID29852A (de)
IL (4) IL142896A0 (de)
MX (1) MXPA01004381A (de)
MY (1) MY122159A (de)
NO (1) NO343240B1 (de)
NZ (1) NZ511442A (de)
PE (1) PE20001322A1 (de)
PL (1) PL205109B1 (de)
PT (1) PT1126826E (de)
RU (1) RU2236847C2 (de)
SK (1) SK287674B6 (de)
TR (1) TR200101216T2 (de)
WO (1) WO2000025752A1 (de)

Families Citing this family (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
AU2004200325B2 (en) * 1998-10-21 2006-09-28 Shire Llc Oral Pulsed Dose Drug Delivery System
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP2020229A1 (de) 1998-11-02 2009-02-04 Elan Pharma International Limited Mehrpartikelmodifizierte Freisetzungszusammensetzung
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
CA2366908A1 (en) * 1999-03-24 2000-09-28 The Secretary Of State For Defence Vaccine composition
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
KR101216270B1 (ko) 1999-10-29 2012-12-31 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6500462B1 (en) * 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
DE60115840T2 (de) * 2000-01-19 2006-07-13 Mannkind Corp., Danbury Formulierung mit mehrfach gepulster wirkstofffreisetzung
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
EP1265598B1 (de) * 2000-03-22 2006-08-02 The Secretary of State for Defence Arzneimittel zur verabreichung an schleimhäute
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
CA2427815C (en) 2000-10-30 2007-07-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
EP1339395A2 (de) * 2000-11-28 2003-09-03 Fmc Corporation Essbare überzugszusammensetzung aus pga (propylenglykolalginat)
WO2002064654A1 (fr) * 2001-02-09 2002-08-22 Reika Kogyo Kabushiki Kaisha Particule fonctionnelle, procede de preparation de celle-ci et procede de traitement par plasma
MXPA03008293A (es) * 2001-03-13 2003-12-11 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
KR100982753B1 (ko) * 2001-04-05 2010-09-16 콜라제넥스 파마슈티칼스, 인크 테트라사이클린 화합물 및 테트라사이클린 유도체의 전달조절
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004032A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US20070254009A1 (en) * 2001-07-13 2007-11-01 Flow Focusing, Inc. Antibiotic/bone morphogenic protein formulation and method of treatment
WO2003005996A1 (en) * 2001-07-13 2003-01-23 Flow Focusing, Inc. Programmable controlled release injectable opioid formulation
US20060263401A1 (en) * 2001-07-13 2006-11-23 Flow Focusing, Inc. Formulation and Method for Preventing Infection
US20070254008A1 (en) * 2001-07-13 2007-11-01 Flow Focusing, Inc. Antibiotic formulation and method of treatment
US20040142013A1 (en) * 2001-07-13 2004-07-22 Flow Focusing, Inc. Implantable orthopedic surgical devices with controlled release antimicrobial component
US20030055075A1 (en) * 2001-07-13 2003-03-20 Rubsamen Reid M. Programmable controlled release injectable opioid formulation
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP2005523876A (ja) * 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
AUPR839001A0 (en) * 2001-10-19 2001-11-15 Eli Lilly And Company Dosage form, device and methods of treatment
ES2351303T3 (es) * 2001-12-11 2011-02-02 University Of Virginia Patent Foundation Utilización de pramipexol para el tratamiento de la esclerosis lateral amiotrófica.
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
JP2005527508A (ja) * 2002-03-07 2005-09-15 ヴェクトゥラ リミテッド 経口デリバリー用急速溶融多粒子製剤
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US7910133B2 (en) * 2002-04-09 2011-03-22 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
US7053034B2 (en) * 2002-04-10 2006-05-30 Salvona, Llc Targeted controlled delivery compositions activated by changes in pH or salt concentration
CA2395819A1 (en) * 2002-08-13 2004-02-13 Bernard Charles Sherman Dual-spike release formulation for oral drug delivery
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
AU2003296852A1 (en) * 2002-09-18 2004-05-04 Elan Corporation, Plc Multiparticulate modified release composition comprising beraprost
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
BR0315731A (pt) * 2002-10-30 2005-09-06 Pharmacia Corp Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
GB0228571D0 (en) 2002-12-06 2003-01-15 Novartis Ag Organic compounds
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
ES2553136T3 (es) 2002-12-13 2015-12-04 Durect Corporation Sistema de administración oral de fármacos que comprende materiales vehículos líquidos de alta viscosidad
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7153526B2 (en) * 2003-02-26 2006-12-26 Frank Steven R Treatment of gastrointestinal infections
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
CA2520321A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US7749532B2 (en) 2003-04-07 2010-07-06 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1648418A4 (de) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005016317A1 (en) * 2003-08-19 2005-02-24 Themis Laboratories Private Limited Process for manufacture of extended release pellets containing diltiazem hci
US8246996B2 (en) 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
EP2260834A2 (de) 2003-09-03 2010-12-15 Mallinckrodt Inc. Granuläres Präparat zur verzögerten Freisetzung und seine Herstellung
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US7906125B2 (en) * 2003-09-18 2011-03-15 Boston Scientific Scimed, Inc. Solid or semi-solid therapeutic formulations
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
MXPA06003101A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
EP1771158A4 (de) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Tablette für pulsierte abgabe
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP2036546B1 (de) * 2004-08-23 2018-10-10 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Psychostimulantium mit einer pharmazeutischen Zusammensetzung
US9149472B2 (en) 2004-08-31 2015-10-06 Jack William Schultz Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
WO2006037080A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Uv cured gel and method of making
US8001922B2 (en) 2004-09-28 2011-08-23 Atrium Medical Corporation Application of a coating on a medical device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060078621A1 (en) * 2004-10-13 2006-04-13 Wedinger Robert S Method of providing customized drug delivery systems
ES2409347T3 (es) 2004-10-21 2013-06-26 Aptalis Pharmatech, Inc. Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
EP2623095A1 (de) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injizierbare Olanzapin-Formulierungen in Nanoteilchenform
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
KR20070087643A (ko) * 2004-12-09 2007-08-28 셀진 코포레이션 D-트레오 메틸페니데이트를 이용한 치료
KR20070116581A (ko) * 2004-12-15 2007-12-10 엘란 파마 인터내셔널 리미티드 나노입자형 타크롤리무스 제제
US20060269596A1 (en) * 2005-01-12 2006-11-30 Gary Liversidge Controlled release compositions comprising an acylanilide
EP1846382A2 (de) * 2005-01-26 2007-10-24 Elan Pharma International Limited Ein antipsychotikum enthaltende zsuammensetzungen mit gesteuerter freisetzung
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
CA2598410A1 (fr) * 2005-02-21 2006-08-24 Flamel Technologies Forme pharmaceutique orale de losartan
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
EP1855651A4 (de) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen heterocyclischer amidderivate
WO2006102964A2 (en) * 2005-03-29 2006-10-05 Evonik Röhm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
CA2604192A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
WO2006110802A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US20090252807A1 (en) * 2005-04-13 2009-10-08 Elan Pharma International Limited Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP2009514989A (ja) * 2005-05-10 2009-04-09 エラン コーポレーション ピーエルシー 改変放出ロキソプロフェン組成物
US20090269400A1 (en) * 2005-05-16 2009-10-29 Elan Pharma International Limited Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
KR20080047509A (ko) * 2005-05-23 2008-05-29 엘란 파마 인터내셔널 리미티드 혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물
EP1954253A4 (de) 2005-06-08 2011-07-27 Elan Pharma Int Ltd Nanoteilchenförmige und kontrolliert freigesetzte zusammensetzungen mit cefditoren
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
JP2009516636A (ja) * 2005-06-13 2009-04-23 エラン コーポレーション ピーエルシー 改変放出チクロピジン組成物
US8263561B2 (en) 2005-06-16 2012-09-11 Amana Pharmaceuticals Corp. Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
WO2007027273A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
JP5095615B2 (ja) 2005-06-27 2012-12-12 バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ ブプロピオン塩の放出調整製剤
US8784851B2 (en) * 2005-07-28 2014-07-22 University Of Hull Topical formulations containing sporopollenin
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
AU2006279643B2 (en) * 2005-08-15 2010-06-17 University Of Virginia Patent Foundation Neurorestoration with R(+) pramipexole
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
KR20080080094A (ko) * 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
JP2009511215A (ja) 2005-10-15 2009-03-19 アトリウム メディカル コーポレーション 生体吸収性薬物担体コーティング用の疎水性架橋ゲル
US20070098796A1 (en) * 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
US20070098791A1 (en) * 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
WO2007062266A2 (en) * 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
KR100762847B1 (ko) * 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
EP1976491B1 (de) * 2006-01-27 2014-12-17 Aptalis Pharmatech, Inc. Wirkstofffreisetzungssysteme mit einem leicht basischen selektiven serotonin-5-blockierungsmittel und organischen säuren
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
KR20140088230A (ko) 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
DK1993357T3 (da) 2006-02-09 2014-04-22 Alba Therapeutics Corp Formuleringer af en tight junction effektor
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
KR20070091960A (ko) * 2006-03-08 2007-09-12 주식회사종근당 졸피뎀 또는 그의 염을 포함하는 안전한 제어방출형 제제조성물
DK2428205T3 (da) 2006-03-16 2012-10-22 Tris Pharma Inc Modificerede formuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
EP2010161A2 (de) * 2006-04-17 2009-01-07 Actavis Group PTC HF Formulierung für orale darreichungsformen und verfahren für ihre zubereitung
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 R(+) 및 s(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
WO2007136664A2 (en) * 2006-05-16 2007-11-29 Flow Focusing, Inc. Antibiotic formulation and method of treatment
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
BRPI0713447A2 (pt) * 2006-06-23 2012-03-13 Elan Pharma International Limited composição forma de dosagem oral sólida, e, método para o tratamento de dor
AU2007260822B2 (en) * 2006-06-23 2012-07-05 Alkermes Pharma Ireland Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
BRPI0714173A2 (pt) * 2006-07-12 2012-12-25 Elan Pharma Int Ltd composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
AU2007275034A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US8889184B2 (en) * 2006-09-07 2014-11-18 Losan Pharma Gmbh Particulate form of a pharmaceutical composition which is easy to swallow
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
MX370905B (es) * 2006-08-31 2020-01-09 Adare Pharmaceuticals Inc Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
ES2524556T3 (es) 2006-10-09 2014-12-10 Charleston Laboratories, Inc. Composiciones farmacéuticas
WO2008052185A2 (en) 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
US8394845B2 (en) * 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
CN101528204B (zh) * 2006-10-30 2012-12-12 韩诺生物制约株式会社 包含血管紧张素Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物
JP2010508897A (ja) 2006-11-06 2010-03-25 アトリウム メディカル コーポレーション コーティングされた外科用メッシュ
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
CA2669410C (en) 2006-11-21 2015-07-14 Mcneil-Ppc, Inc. Modified release analgesic suspensions
KR20090091321A (ko) * 2006-11-28 2009-08-27 마리누스 파마슈티컬스 나노입자 제형, 이의 제조방법 및 이의 용도
EP2363113B1 (de) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Topiramat-Formulierungen für verstärkte unmittelbare Freisetzung
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
NZ598477A (en) 2007-02-20 2012-11-30 Aptalis Pharma Ltd Stable digestive enzyme compositions
US20080227805A1 (en) * 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
EP2137171A4 (de) 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthese von chiralaufgereinigten substituierten benzothiazoldiaminen
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
US20080318994A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
WO2009058798A2 (en) 2007-10-31 2009-05-07 Mcneil-Ppc, Inc. Orally disintegrated dosage form
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
KR101569604B1 (ko) 2007-12-28 2015-11-16 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
EP3090743A1 (de) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) * 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CA2627198A1 (en) * 2008-03-27 2009-09-27 Pharmascience Inc. Methylphenidate extended release therapeutic drug delivery system
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
GB0812513D0 (en) * 2008-07-09 2008-08-13 Univ Hull Delivery vehicle
JP2012500283A (ja) 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク. (r)−プラミペキソールを使用した組成物並びにその方法
DE102008048729A1 (de) * 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2009311877C1 (en) * 2008-11-07 2013-08-15 Samyang Holdings Corporation Pharmaceutical composition for release control of methylphenidate
WO2010053337A2 (ko) * 2008-11-10 2010-05-14 (주)아모레퍼시픽 서방성 미립자 및 이의 제조방법
US8551517B2 (en) * 2008-12-16 2013-10-08 Kimberly-Clark Worldwide, Inc. Substrates providing multiple releases of active agents
WO2010078486A2 (en) 2008-12-31 2010-07-08 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
DK2395840T3 (da) 2009-02-13 2020-06-08 Romark Laboratories Lc Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
SG175137A1 (en) * 2009-04-09 2011-11-28 Alkermes Pharma Ireland Ltd Drug delivery composition
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Th1 편향 반응을 제공하는 면역나노치료법
MX360019B (es) * 2009-04-24 2018-10-15 Iceutica Pty Ltd Una formulación novedosa de metaxalona.
EA201791383A1 (ru) 2009-05-27 2018-06-29 Селекта Байосайенсиз, Инк. Наноносители, имеющие компоненты с различными скоростями высвобождения
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
BR112012008317A2 (pt) 2009-09-17 2016-03-22 Upsher Smith Lab Inc produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
US8343533B2 (en) * 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
EP2506836B1 (de) 2009-12-02 2018-02-14 Adare Pharmaceuticals S.R.L. Fexofenadin-mikrokapseln und zusammensetzungen damit
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
NO2575876T3 (de) 2010-05-26 2018-05-05
MY167126A (en) * 2010-06-16 2018-08-13 Takeda Pharmaceuticals Usa Inc Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
EP2593141B1 (de) 2010-07-16 2018-07-04 Atrium Medical Corporation Zusammensetzung und verfahren zur veränderung der geschwindigkeit einer hydrolyse ausgehärteter materialien auf ölbasis
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2012030885A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
US8703943B2 (en) 2010-09-01 2014-04-22 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
CN101933913A (zh) * 2010-09-16 2011-01-05 孙卫东 一种盐酸右哌甲酯双释放制剂及其制备方法
WO2012040710A2 (en) * 2010-09-24 2012-03-29 Case Western Reserve University Stabilized nanobubbles for diagnostic and therapeutic applications
BR112013007640A2 (pt) 2010-10-01 2017-09-26 Aptalis Pharma Ltd "composição, forma de dosagem, pacote, processo para a preparação da composição, processo para a preparação da forma de dosagem, método para tratamento ou prevenção de um distúrbio ou afecção associada a uma defeciência de enzima digestiva, método de terapia de substituição de enzima pacnreática e método para aperfeiçoar resultados nutricionais e de crescimento"
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
MX2021000431A (es) 2011-03-23 2022-10-28 Ironshore Pharmaceuticals & Dev Inc Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2830948A1 (en) * 2011-03-25 2012-10-04 Selecta Biosciences, Inc. Osmotic mediated release synthetic nanocarriers
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
CN103458859A (zh) 2011-04-07 2013-12-18 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的个人清洁组合物
WO2012138690A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Conditioner compositions with increased deposition of polyacrylate microcapsules
MX2013010983A (es) 2011-04-07 2013-10-30 Procter & Gamble Composiciones de champu con deposito mejorado de microcapsulas de poliacrilato.
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
EP2736537A4 (de) 2011-07-29 2015-04-15 Selecta Biosciences Inc Synthetische nanotransporter zur erzeugung humoraler und cytotoxischer t-lymphocy (ctl)-immunreaktionen
JP6004549B2 (ja) 2011-08-08 2016-10-12 アプタリス ファーマ リミテッドAptalis Pharma Limited 消化酵素を含む組成物の溶出試験の方法
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
CN102429884A (zh) * 2011-12-29 2012-05-02 天津市嵩锐医药科技有限公司 盐酸哌甲酯口腔崩解药物组合物
AU2013205306B2 (en) 2012-03-16 2015-09-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
KR20150027800A (ko) 2012-06-15 2015-03-12 고에키 자이단 호징 센탄 이료 신코 자이단 경도 인지 장해의 예방 및/또는 치료제
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US20140161879A1 (en) * 2012-07-31 2014-06-12 Zogenix, Inc. Treating pain in patients with hepatic impairment
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
ES2717469T3 (es) 2012-08-15 2019-06-21 Tris Pharma Inc Comprimido masticable de metilfenidato de liberación prolongada
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
RU2015146324A (ru) 2013-03-29 2017-05-15 Вокхардт Лимитед Фармацевтические композиции модифицированного высвобождения дексметилфенидата или его солей
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
EP3019167B1 (de) 2013-07-12 2021-02-17 Knopp Biosciences LLC Behandlung eines erhöhten spiegels von eosinophilen und/oder basophilen
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RU2679832C2 (ru) 2013-08-09 2019-02-13 Аллерган Фармасьютикалз Интернэйшнл Лимитед Композиция пищеварительных ферментов, подходящая для энтерального введения
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
KR102266091B1 (ko) 2013-10-07 2021-06-17 임팩스 라보라토리즈, 인코포레이티드 레보도파 및/또는 레보도파의 에스테르의 점막-점착성, 제어 방출형 제제 그리고 이의 용도
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015065497A1 (en) * 2013-11-04 2015-05-07 Schultz Jack William Treatment of cognitive, emotional and mental ailments and disorders
CA2936216C (en) 2014-01-10 2021-10-26 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
JP6568926B2 (ja) 2014-03-20 2019-08-28 カペラ セラピューティクス,インコーポレーテッド 癌の治療のためのerbbチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
TWI683813B (zh) 2014-03-20 2020-02-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
AU2015275860A1 (en) 2014-06-19 2016-11-03 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
KR101686986B1 (ko) 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3193845A1 (de) 2014-09-19 2017-07-26 The Procter and Gamble Company Darreichungsformen von phenylephrin mit gepulster freisetzung
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
GB201420306D0 (en) * 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
WO2016090168A1 (en) * 2014-12-03 2016-06-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EA032473B1 (ru) 2014-12-23 2019-05-31 Аксикин Фармасьютикалз, Инк. 3,5-диаминопиразоловые ингибиторы киназы
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
JP2018530585A (ja) 2015-10-16 2018-10-18 マリナス ファーマシューティカルズ インコーポレイテッド ナノ粒子を含む注射可能な神経ステロイド製剤
FI3365321T3 (fi) 2015-10-23 2024-01-02 B3Ar Therapeutics Inc Solabegron-Zwitterioni ja sen käyttöjä
US20170296476A1 (en) * 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
EP3463312A4 (de) * 2016-06-03 2020-02-05 Velicept Therapeutics, Inc. Dosierschemata für beta-3-adrenozeptoragonisten und antimuskarinika zur behandlung und vorbeugung von symptomen der unteren harnwege und überaktiver blase
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
EP3585439A4 (de) 2016-11-01 2020-07-22 Neos Therapeutics, LP Wirksame dosierung für kinder zur behandlung von adhd mit methylphenidat
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US10555986B2 (en) * 2017-03-23 2020-02-11 Instituto De Capacitación E Investigación Del Plás Dietary supplement derived from natural prodcuts by hot melt extrusion (HME) processing
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2020104955A1 (en) * 2018-11-20 2020-05-28 Dr. Reddy’S Laboratories Limited Pharmaceutical compositions of acotiamide and proton pump inhibitor
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1082206A (en) 1963-07-02 1967-09-06 Applic Chimiques D Etudes & De Improved antibiotic medicine
US4330626A (en) 1980-03-19 1982-05-18 The Enzyme Center, Inc. Method of preparing high-activity, low-bacteria, urease enzyme
US4539199A (en) 1981-01-14 1985-09-03 Egyt Gyogyszervegyeszeti Gyar Sustained release pharmaceutical compositions
JPS5826816A (ja) 1981-08-11 1983-02-17 Teisan Seiyaku Kk 球形顆粒からなる持続性複合顆粒剤
EP0076158B1 (de) * 1981-09-30 1989-10-25 National Research Development Corporation Zusammensetzungen die eingekapselte Teilchen enthalten
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DE3405378A1 (de) 1984-02-15 1985-08-22 Röhm GmbH, 6100 Darmstadt Arzneimittelueberzug
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
NL8500724A (nl) 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
EP0212747B1 (de) 1985-08-16 1991-04-10 The Procter & Gamble Company Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller Freisetzung
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4986987A (en) * 1986-05-09 1991-01-22 Alza Corporation Pulsed drug delivery
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US4948586A (en) 1987-11-02 1990-08-14 Lim Technology Laboratories, Inc. Microencapsulated insecticidal pathogens
US4844896A (en) 1987-11-02 1989-07-04 Lim Technology Laboratories, Inc. Microencapsulated insecticidal pathogens
US4971805A (en) 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
US5460817A (en) 1988-01-19 1995-10-24 Allied Colloids Ltd. Particulate composition comprising a core of matrix polymer with active ingredient distributed therein
EP0406315B1 (de) 1988-03-24 1992-11-11 Bukh Meditec A/S Geregelte verabreichungszusammensetzung
MC2025A1 (fr) 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US4956182A (en) 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JPH0674206B2 (ja) 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
GB9010431D0 (en) 1990-05-09 1990-06-27 Mead Corp Wraparound multipack with carrying handle
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
US5232705A (en) * 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
CA2112905A1 (en) 1991-07-05 1993-01-21 Michael R. Violante Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5226902A (en) 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
WO1993006821A1 (en) 1991-10-04 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
EP0546593B1 (de) * 1991-10-30 1997-09-03 Glaxo Group Limited Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5654006A (en) 1993-02-12 1997-08-05 Mayo Foundation For Medical Education And Research Condensed-phase microparticle composition and method
US5820879A (en) 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
US5753261A (en) 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition
US5264610A (en) 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5436011A (en) 1993-04-16 1995-07-25 Bristol-Myers Squibb Company Solid pharmaceutical dosage form and a method for reducing abrasion
DE69425453T2 (de) 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ES2068762B1 (es) * 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
US5362442A (en) 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
CA2128821A1 (en) 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5380790A (en) 1993-09-09 1995-01-10 Eastman Chemical Company Process for the preparation of acrylic polymers for pharmaceutical coatings
GB9319568D0 (en) * 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
US6123900A (en) 1993-10-28 2000-09-26 Vellutato; Arthur L. Method of sterilization
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
JPH08175977A (ja) * 1994-09-16 1996-07-09 Euro Celtique Sa アクリル系ポリマーの水性分散液で被覆した放出制御型製剤及びその製法
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
JPH08137062A (ja) * 1994-11-07 1996-05-31 Konica Corp ハロゲン化銀写真感光材料用定着液及び該定着液を用いた処理方法
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
US5872104A (en) 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
GB9514451D0 (en) * 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
JPH11509227A (ja) 1995-07-14 1999-08-17 カイロサイエンス・リミテッド d−トレオ−メチルフェニデートの治療的使用
DE19526759A1 (de) 1995-07-21 1997-01-23 Wacker Chemie Gmbh Redispergierbare, vernetzbare Dispersionspulver
DE19529445A1 (de) 1995-08-10 1997-02-13 Basf Ag Verwendung von Polymerisaten auf Basis von Ethylen, (Meth)acrylsäureestern und (Meth)acrylsäure zum Beschichten oder Versiegeln von Verbundsicherheitsglasscheiben
AR004014A1 (es) * 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
US5807579A (en) 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
SE9600046D0 (sv) 1996-01-05 1996-01-05 Astra Ab New pharmaceutical formulation
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ES2200158T3 (es) * 1996-03-08 2004-03-01 Nycomed Danmark Aps Cmpuesto de dosificacion de unidades multiples, de liberacion modificada.
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
JP4393587B2 (ja) 1996-08-16 2010-01-06 アルザ コーポレイション 医薬の上昇性投与量を提供するための薬剤投与型
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
CA2264852C (en) 1996-09-30 2005-11-01 Alza Corporation Use of methylphenidate or a pharmaceutically acceptable salt thereof
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
DE19653631A1 (de) 1996-12-20 1998-06-25 Basf Coatings Ag Verfahren zum Herstellen von durch Strahlung vernetzbaren polymeren Acryl- oder Methacrylsäureestern
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US5776856A (en) 1997-02-04 1998-07-07 Isp Investments Inc. Soluble polymer based matrix for chemically active water insoluble components
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
IL133081A (en) 1997-07-01 2005-09-25 Pfizer Prod Inc Delayed release dosage forms of sertraline
GB9714675D0 (en) 1997-07-11 1997-09-17 Smithkline Beecham Plc Novel composition
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
AU9062998A (en) * 1997-09-11 1999-03-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
KR100377916B1 (ko) 1997-09-26 2003-03-29 와커-헤미 게엠베하 보호콜로이드로 안정화시킨 폴리머의 제조방법
US6327254B1 (en) 1997-10-14 2001-12-04 Lucent Technologies Inc. Method for bandwidth sharing in a multiple access system for communications networks
AU1827799A (en) * 1997-12-15 1999-07-05 Axia Therapeutics, Inc. Oral delivery formulation
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6066292A (en) 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
US6004584A (en) 1998-03-02 1999-12-21 The Procter & Gamble Company Highly absorbent body powders
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
JP2002516848A (ja) * 1998-06-03 2002-06-11 アルザ・コーポレーション 長時間の薬物療法を与える方法および装置
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
EP2020229A1 (de) * 1998-11-02 2009-02-04 Elan Pharma International Limited Mehrpartikelmodifizierte Freisetzungszusammensetzung
IT1303692B1 (it) 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
MXPA01006108A (es) * 1998-12-17 2002-09-18 Alza Corp Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.
US6524528B1 (en) 1999-03-02 2003-02-25 Suzanne C. Gottuso Method of sterilizing a tattooing solution through irradiation
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6025502A (en) 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US6217904B1 (en) 1999-04-06 2001-04-17 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
WO2000072973A1 (en) 1999-06-01 2000-12-07 Elan Pharma International Ltd. Small-scale mill and method thereof
US6596230B1 (en) 2000-01-28 2003-07-22 Baxter International Inc. Device and method for pathogen inactivation of therapeutic fluids with sterilizing radiation
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
JP2001316294A (ja) 2000-03-14 2001-11-13 Pfizer Prod Inc o−バニリンおよびo−バニリン/テトラメチルクロマニルカルボン酸化合物の組み合わせの使用法
EA005977B1 (ru) 2000-03-23 2005-08-25 Клиарант, Инк. Способы стерилизации биологических материалов
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
US20040026546A1 (en) 2000-04-26 2004-02-12 Czekai David A Apparatus for sanitary wet milling
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
US20030219461A1 (en) 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20030095928A1 (en) 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
ATE464880T1 (de) 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
WO2004019901A2 (en) * 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition
ES2355723T3 (es) 2002-09-11 2011-03-30 Elan Pharma International Limited Composiciones de agente activo en nanopartículas estabilizadas en gel.
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
JP4739217B2 (ja) * 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
JP2007501839A (ja) 2003-08-08 2007-02-01 エラン ファーマ インターナショナル リミテッド 新規メタキサロン組成物
US7494950B2 (en) * 2003-09-05 2009-02-24 Synthes (U.S.A.) Bone cement compositions having fiber-reinforcement and/or increased flowability
AR046410A1 (es) * 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
WO2005112970A2 (en) * 2004-05-12 2005-12-01 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
JP2008540546A (ja) 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
CN101237868A (zh) 2005-06-13 2008-08-06 伊兰制药国际有限公司 纳米粒氯吡格雷和阿司匹林组合制剂

Also Published As

Publication number Publication date
IL142896A0 (en) 2002-04-21
RU2236847C2 (ru) 2004-09-27
US20030129237A1 (en) 2003-07-10
IL211075A (en) 2012-03-29
EP1126826B1 (de) 2008-10-15
ID29852A (id) 2001-10-18
SK287674B6 (sk) 2011-05-06
IL142896A (en) 2007-03-08
EP1126826B3 (de) 2019-05-15
EP2020229A1 (de) 2009-02-04
ES2313797T7 (es) 2019-11-19
KR20070051953A (ko) 2007-05-18
NO20012139D0 (no) 2001-04-30
HU230454B1 (hu) 2016-07-28
NZ511442A (en) 2003-02-28
BR9914977A (pt) 2001-12-11
JP5463223B2 (ja) 2014-04-09
US20110008435A1 (en) 2011-01-13
NO20012139L (no) 2001-06-27
NO343240B1 (no) 2018-12-17
CN1403076A (zh) 2003-03-19
JP4613275B2 (ja) 2011-01-12
EP1126826A4 (de) 2004-05-06
EP1126826B9 (de) 2009-07-08
US6793936B2 (en) 2004-09-21
US6228398B1 (en) 2001-05-08
AU770645B2 (en) 2004-02-26
PL205109B1 (pl) 2010-03-31
PT1126826E (pt) 2008-11-25
US6730325B2 (en) 2004-05-04
AU1335000A (en) 2000-05-22
CZ303495B6 (cs) 2012-10-24
CN100444830C (zh) 2008-12-24
EP1126826A1 (de) 2001-08-29
CA2653839A1 (en) 2000-05-11
IL179379A0 (en) 2007-03-08
AU2004202078A1 (en) 2004-07-01
DK1126826T3 (da) 2009-01-19
MXPA01004381A (es) 2005-09-08
US20030170304A1 (en) 2003-09-11
CN1335768A (zh) 2002-02-13
CA2348871A1 (en) 2000-05-11
DK1126826T5 (en) 2018-10-22
SK5992001A3 (en) 2001-12-03
PE20001322A1 (es) 2000-11-30
CO5261536A1 (es) 2003-03-31
DK1126826T6 (en) 2019-06-24
TR200101216T2 (tr) 2001-08-21
PL348633A1 (en) 2002-06-03
IL211075A0 (en) 2011-04-28
US20080279929A1 (en) 2008-11-13
KR20080032661A (ko) 2008-04-15
AU2004202078B2 (en) 2005-09-22
BRPI9914977B8 (pt) 2021-05-25
IL179379A (en) 2011-03-31
HUP0104039A3 (en) 2002-04-29
AU2005247019B2 (en) 2007-05-24
BR9914977B1 (pt) 2014-03-11
HK1050487A1 (en) 2003-06-27
AU2009201786A1 (en) 2009-05-28
AU2009201786B2 (en) 2012-02-23
US8119163B2 (en) 2012-02-21
JP2010270128A (ja) 2010-12-02
ES2313797T3 (es) 2009-03-01
EP2311442A1 (de) 2011-04-20
US6902742B2 (en) 2005-06-07
CZ20011539A3 (cs) 2001-12-12
AR021858A1 (es) 2002-08-07
US20040197405A1 (en) 2004-10-07
AU2005247019A1 (en) 2006-02-02
ATE411011T3 (de) 2008-10-15
KR100812832B1 (ko) 2008-03-11
WO2000025752A1 (en) 2000-05-11
CA2348871C (en) 2009-04-14
CY1110421T1 (el) 2015-04-29
JP2002528485A (ja) 2002-09-03
HUP0104039A2 (hu) 2002-03-28
KR20010111563A (ko) 2001-12-19
MY122159A (en) 2006-03-31
US20020054907A1 (en) 2002-05-09

Similar Documents

Publication Publication Date Title
DE69939748D1 (de) Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
ATE252386T1 (de) Galantamin-zusammensetzung mit gesteuerter freisetzung
IS5430A (is) Ný samsetning
ATE239011T1 (de) Neuartige form von s-omeprazol
ATE275975T1 (de) Mikroverkapselte ngf zusammensetzungen mit geregelter freigabe
ID22970A (id) Komposisi perekat
ID26964A (id) Komposisi dan metode untuk pengaturan pengaktifan limfosit
DE69739738D1 (de) Epoxy-Polysiloxan-Polymer-Zusammensetzung
ID28965A (id) Azabisikloalkana sebagai modulator ccr5
ID26186A (id) Komposisi sampo
ID26926A (id) Komposisi shampo pembentuk mode
ID22889A (id) Komposisi kopolimer etilena dan penggunaannya
NO20002470L (no) Ny materialsammensetning
PT945132E (pt) Composicao de ibuprofeno
DE69704183T2 (de) Bohrlochzementzusammensetzung
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
ID29430A (id) Komposisi herbisida
ID25508A (id) Komposisi dematologis
ID24196A (id) Komposisi dan penggunaan
DE69833249D1 (de) Harzzusammensetzung
DE69841155D1 (de) Emulsionzusammensetzung
DE69928862D1 (de) Zusammensetzung
DE69936140D1 (de) Klebstoffzusammensetzung
ID23250A (id) Komposisi paroksetin
DE69811141D1 (de) Klebstoffzusammensetzung

Legal Events

Date Code Title Description
8363 Opposition against the patent